The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -167,303 | - |
| Depreciation and amortization | 745 | 1,120 |
| Share-based compensation expense | 3,709 | 5,599 |
| Net periodic pension benefit gain for the qualified pension plan | -18 | -9 |
| Other non-cash items | -283 | 1,211 |
| Other receivables | 612 | 566 |
| Operating lease right-of-use assets | 0 | 0 |
| Prepaid expenses | -274 | 3,570 |
| Other non-current assets | -1,110 | 1,697 |
| Trade and other payables | 8,203 | 8,087 |
| Operating lease liabilities | -401 | -444 |
| Accrued expenses and other current liabilities | 12,856 | -3,368 |
| Net cash flow used in operating activities | -44,543 | -92,670 |
| Purchase of short-term marketable debt securities | 0 | 206,207 |
| Proceeds from maturities of short-term marketable debt securities | 88,403 | 350,742 |
| Purchase of property and equipment | 0 | 35 |
| Net cash flow provided by (used in) investing activities | 88,403 | 144,500 |
| Proceeds from options exercised under esop | - | 100 |
| Proceeds from long-term debt, net of issuance costs | 0 | 73,022 |
| Issuance of class a ordinary shares, net of transaction costs | 0 | 0 |
| Stamp duty on capital injection from moonlake to moonlake ag | 0 | 0 |
| Proceeds from options exercised-Equity Incentive Plan | 480 | - |
| Proceeds from options exercised-Employee Stock Option Plan ESOP | 100 | - |
| Net cash flow provided by financing activities | 480 | 73,122 |
| Effect of movements in exchange rates on cash held | -285 | 1,303 |
| Net change in cash and cash equivalents | 44,055 | 126,255 |
| Cash and cash equivalents at beginning of period | 180,426 | - |
| Cash and cash equivalents at end of period | 350,736 | - |
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)